

A Phase 1/2A, (Part B, participant-, investigator-, and sponsor-blind) study; to investigate the safety, pharmacokinetics, and efficacy (Part B only) of UCB1381 in study participants with moderate to severe atopic dermatitis;(Part B)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18-65 years of age - moderate to severe itch

Exclusion Criteria:

- diabetes not well controlled with diet - history of Crohns disease or Colitis

Conditions & Interventions

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

Atopic Dermatitis

More Information

Description: This is an early study of a new drug called UCB1381. In the first part of the study, we are looking at increasing doses of the drug when compared to an inactive drug (placebo) when given to healthy participants. In the second part, we will look at the safety and effectiveness of one dose of UCB1381 compared to an inactive drug (placebo) when given to people who have moderate to severe Atopic Dermatitis.

Study Contact: Sydney Lo - lo000109@umn.edu

Principal Investigator: Paul Bigliardi

IRB

Number: SITE00001885

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.